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Complement receptor CD46 co-stimulates optimal
human CD8+ T cell effector function via fatty acid
metabolism
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The induction of human CD4+ Th1 cells requires autocrine stimulation of the complement
receptor CD46 in direct crosstalk with a CD4+ T cell-intrinsic NLRP3 inflammasome.
However, it is unclear whether human cytotoxic CD8+ T cell (CTL) responses also rely on an
intrinsic complement-inflammasome axis. Here we show, using CTLs from patients with
CD46 deficiency or with constitutively-active NLRP3, that CD46 delivers co-stimulatory
signals for optimal CTL activity by augmenting nutrient-influx and fatty acid synthesis. Sur-
prisingly, although CTLs express NLRP3, a canonical NLRP3 inflammasome is not required for
normal human CTL activity, as CTLs from patients with hyperactive NLRP3 activity function
normally. These findings establish autocrine complement and CD46 activity as integral
components of normal human CTL biology, and, since CD46 is only present in humans,
emphasize the divergent roles of innate immune sensors between mice and men.
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The liver-derived serum-circulating complement system isclassically recognized as a key sensor system that isrequired for the rapid detection and removal of pathogenic
microbes. Activation of C3 into C3a and C3b and of C5 into C5a
and C5b upon microbe sensing mediates the opsonization and
subsequent uptake of the pathogen by scavenger cells, the
migration and activation of innate immune cells to the pathogen
entry side, and the initiation of the general inflammatory
response1. Importantly, the complement system serves an equally
profound role in the direct regulation of human CD4+ T-cell
responses. Optimal T helper type 1 (Th1) induction from CD4+
T cells in rodents and humans requires T-cell receptor (TCR)
activation, co-stimulatory signals and environmental interleukin
(IL)-122. However, while CD28-ligation signals provide largely
sufficient T-cell co-stimulation in mouse T cells3, additional
signals delivered by the complement regulators/receptor CD46
(membrane cofactor protein, MCP) and the C3a receptor (C3aR)
are essential to normal Th1 induction in humans4–6.
Unexpectedly, many T-cell-modulating functions of complement
are independent of serum-circulating complement and are instead
driven by T-cell-generated, autocrine, complement activation frag-
ments, which engage complement receptors expressed within the
cell’s interior compartments and on the surface of T cells (Sup-
plementary Fig. 1a). Specifically, during TCR activation, C3 is
cleaved intracellularly by the protease cathepsin L, which leads to
intracellular as well as surface secreted C3a and C3b generation7.
C3a binds to the G protein-coupled receptor (GPCR) C3aR and
C3b engages the complement receptor and regulator CD468. These
receptors can be expressed intracellularly and extracellularly by the
T cells and are engaged during T-cell activation in an autocrine
manner. CD46 is a signaling transmembrane protein and expressed
as discrete isoforms bearing one of two distinct cytoplasmic
domains, CYT-1 or CYT-2—with CYT-1 driving interferon (IFN)-
γ induction in CD4+ T cells9. Autocrine CD46 engagement during
T-cell stimulation drives nutrient influx and assembly of the lyso-
somal mammalian target of rapamycin complex 1 (mTORC1) and
the glycolytic and oxidative phosphorylation metabolic pathways
specifically required for IFN-γ secretion and Th1 lineage induction
(Supplementary Fig. 1a)9,10.
CD46 engagement simultaneously also triggers intracellular C5
cleavage into C5a and C5b within CD4+ T cells. The stimulation
of intracellular C5aR1 receptor by C5a drives the generation of
reactive oxygen species (ROS) and via this the assembly of the
canonical NLR family pyrin domain containing 3 (NLRP3)
inflammasome in CD4+ T cells11. NLRP3 inflammasome-
generated mature IL-1β further supports IFN-γ generation in
CD4+ T cells and sustains Th1 responses in tissues in an auto-
crine fashion (Supplementary Fig. 1a). Accordingly, C3- and
CD46-deficient patients have severely reduced Th1 responses and
suffer from recurrent bacterial and viral infections12,13, while
mice lacking NLRP3 expression in CD4+ T cells have diminished
Th1 activity during lymphocytic choriomeningitis virus infec-
tion11. Uncontrolled intracellular C3 activation in CD4+ T cells,
on the other hand, has been shown to contribute to the patho-
logically increased Th1 responses that accompany several auto-
immune diseases4,14. Importantly, these C3-driven responses can
be pharmacologically normalized with a cell-permeable cathepsin
L inhibitor that reduces intracellular C3 activation back to normal
levels7. Aligning with a key role for the NLRP3 inflammasome in
sustaining the human Th1 response, CD4+ T cells from patients
that suffer from cryopyrin-associated periodic syndromes (CAPS)
due to gain-of-function mutations in NLRP3, display also sig-
nificantly increased IFN-γ production. The hyperactive Th1
immunity in CAPS patients can be corrected (at least in vitro)
through inhibition of the T-cell-intrinsic NLRP3 inflammasome
with the specific pharmacological NLRP3 inhibitor MCC95011,15.
Thus, an intracellular complement (the complosome) and
NLRP3 inflammasome crosstalk operating at minimum through
the regulation of key metabolic pathways is required for normal
human Th1 induction in CD4+ T cells (Supplementary Fig. 1a).
Importantly, CD46 is not expressed on somatic tissues in rodents
and a functional homolog has not yet been identified8. In addi-
tion, NLRP3 expression in mouse CD4+ T cells seems to be
required for Th2 responses16, whilst there is currently no evi-
dence that NLRP3 supports human Th2 activity11. Altogether
these observations suggest that the (innate) pathways controlling
CD4+ T-cell responses are profoundly different between mice
and men and that a better understanding of the human-specific
drivers will likely inform on the divergent molecular mechanism
underlying human T-cell-driven pathological conditions and
should lead to improved (preclinical) animal models for the
development of better therapeutic interventions targeting such
diseases.
While the instructive role of complement in human CD4+ T-
cell immunity is now being increasingly recognized, there is little
knowledge about complement’s impact on human CD8+ T-cell
responses17,18. Given the critical roles of CD46 and NLRP3 in
IFN-γ production by CD4+ T cells, here we assess whether an
intrinsic complosome-NLRP3 inflammasome axis is also required
for the induction of cytokine production and/or cytotoxicity in
CD8+ T cells. Surprisingly, and opposed to CD4+ T cells,
CD46 stimulation is not obligatory for the initial induction of
IFN-γ and tumor necrosis factor (TNF)-α production and cyto-
toxicity in CD8+ T cells. However, CD46 is critical for the
optimal induction of CTL activity (IFN-γ secretion and cyto-
toxicity) and emerges as superior co-stimulator that is required
for normal levels of amino acid (AA) influx and subsequent
mTOR activation as well as augmentation of fatty acid synthase
(FASN) expression during TCR activation. Furthermore,
although CD8+ T cells indeed express NLRP3, neither inhibition
nor potentiation of NLRP3 inflammasome function alters CD8+
T-cell activity. Thus, autocrine complement and the inflamma-
somes play important but divergent roles in human CD4+ and
CD8+ T cells. These findings help explaining why CD46-deficient
patients suffer from recurrent viral infections11,13 and could also
indicate that NLRP3 inflammasome-targeted therapeutics may
not directly interfere with protective CTL activity.
Results
CD46 provides superior support for CTL effector function. We
have previously shown that autocrine activation of CD46 in
human CD4+ T cells during TCR stimulation drives metabolic
reprogramming and the assembly of an intrinsic NLRP3
inflammasome, both events critically required for normal Th1
induction and contraction11 (Supplementary Fig. 1a). We hypo-
thesized the existence of a functionally important similar system
in human CD8+ T cells. In freshly isolated healthy donor CD8+
T cells (CD8+/CD56–) we first observed that surface CD46 is
expressed at levels comparable to those of CD4+ T cells (Fig. 1a),
with a similar isoform pattern with regards to the cytoplasmic tail
expression (CYT-1 versus CYT-2) (Supplementary Fig. 1b).
Functionally, engagement of CD46 by antibodies during T-cell
activation significantly enhanced production of the key effector
cytokines IFN-γ and TNF-α in both CD8+ and CD4+ T cells
when compared to CD3 or CD3+CD28 stimulation (Fig. 1b). In
addition, CD46 stimulation significantly increased degranulation,
as measured by appearance of CD107a on the cell surface,
granzyme B expression and killing capacity in CD8+ T cells
(Fig. 1c–e and Supplementary Fig. 1c). Of note, CD46 activation
without concurrent CD3 stimulation had no measurable impact
on CD8+ T-cell activation, suggesting that CD46 fulfills an
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important co-stimulatory role in CTLs. Importantly, while CD46
is also critical for the co-induction of immunosuppressive IL-10
in human Th1 cells as part of Th1 contraction program4, CD46
engagement on CD8+ T cells failed to induce IL-10 (Fig. 1b).
Likewise, CD46 stimulation, did not augment CD8+ T-cell
proliferation and had no effect on cell viability when compared to
CD3 or CD3+ CD28 activation (Fig. 1f and Supplementary
Fig. 1d). Finally, CD46 significantly augmented the amount of
IFN-γ secretion and numbers of CD107a and granzyme B
double-positive cells, as well as cytotoxic activity when compared
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to CD28 co-stimulation in both sorted naive and memory CD8+
T cells (Fig. 1g).
To assess if CD46 engagement provides more potent co-
stimulation regardless of TCR and/or CD28 signal strength, we
titered the amounts of antibodies used to activate CTLs and
measured subsequent IFN-γ secretion. These experiments
demonstrated that amplified TCR and CD28 stimulation pro-
portionally increased cytokine production by CTLs but that CD46
remained the strongest stimulus throughout the activation
conditions tested (Fig. 2a). Moreover, we had previously shown
that autocrine CD46 activation on CD4+ T cells by TCR and
CD28-driven generation of C3b is an integral and non-redundant
part of human Th1 cell induction9. Such autocrine CD46
activation machinery seems to also exist in CD8+ T cells: CD8
+ T cells contained intracellular stores of the C3aR, C3, and C3a
as previously observed in CD4+ T cells (Fig. 2b–c and
Supplementary Fig. 2a)7. Also in line with our observations in
CD4+ T cells7, activation of CTLs with increasing amounts of
anti-CD3 and/or anti-CD28 antibodies was associated with
greater surface deposition of C3b as well as a simultaneous
proportional increase in CD107a and granzyme B expression
(Fig. 2d) and IFN-γ secretion (Fig. 2e). In addition, activation of
CTLs in the presence of a cell-permeable cathepsin L inhibitor
(which prevents intracellular C3 activation in CD4+ T cells7) also
reduced C3b surface levels, degranulation and granzyme B
expression, and IFN-γ secretion significantly in CTLs (Supple-
mentary Fig. 2b, c). This strongly suggests that modulation of
CTL activity by varying TCR and co-stimulatory signal strength
was indeed impacted by autocrine CD46-mediated signaling. It
should be noted though that the effects of cathepsin L inhibition
on diminished CTL activity may not solely be attributable to
reduction in intracellular C3 activation as we cannot exclude that
cathepsin L inhibition had also a direct effect—at minimum—on
perforin activation and hence cytotoxic activity in CTLs19.
Collectively, these data indicate that autocrine CD46 ligation,
driven by TCR and CD28-mediated generation of C3b, provides
superior co-stimulatory signals that support effector functions in
human CD8+ T cells.
CD46 signals synergize with TCR signals for CTL activity. The
complete absence of autocrine CD46 engagement in CD4+ T cells
impedes human Th1 induction even in the presence of normal
TCR and CD28 signals9,13. To define whether CD46 activity is
also obligatory for the induction of effector function in CD8+
T cells, we utilized T cells from four CD46-deficient patients (as
CD46 inhibitors or blocking reagents are not available) (Sup-
plementary Table 1). These patients suffer from atypical hemo-
lytic uremic syndrome and impaired Th1 responses13,20–22. All
patients show no or barely detectable CD46 expression on CD8+
T cells but normal CD3 and CD28 expression levels (Fig. 3a,
Supplementary Fig. 3a and Supplementary Table 2). Also, their
respective proportion of memory CD8+ T cells falls within the
typical range when compared to age- and sex-matched healthy
donors (Supplementary Fig. 3b), indicating that CD46 deficiency
is not accompanied by a developmental CD8+ T-cell defect.
Figure 3a–d shows the analysis of all CD4+ and CD8+ T-cell
effector functions in detail for Patient CD46-1. As previously
demonstrated, CD4+ T cells from this patient produced negligible
IFN-γ (or IL-10)13 under any activation conditions tested when
compared to a healthy donor (Fig. 3b). Unexpectedly though,
CD3 stimulated CD8+ T cells from this patient demonstrated
unimpaired IFN-γ secretion (Fig. 3b). TCR triggering in the
presence of either CD28 or CD46 stimulating antibodies, how-
ever, failed to induce the optimal IFN-γ secretion that is seen in
CTLs from healthy donors (Fig. 3b). The CD3 and CD3+ CD28-
triggered basal levels of degranulation, granzyme B expression
and cytotoxicity were unaltered in the patient’s CD8+ T cells but
no additional increment was observed with CD46 co-ligation
(Fig. 3c, d). Importantly, analyses of CTL responses from three
additional CD46-deficient patients (CD46-2 to -413,21,22) corro-
borated these observations and confirmed a significant reduction
in IFN-γ production upon CD28 or CD46 co-stimulation
(Fig. 3e) and lack of CD46-driven increase in degranulation
and granzyme B expression (Fig. 3f and Supplementary Fig. 3c)
by CD8+ T cells with inadequate CD46 expression. CTL
responses from the patients remained ‘‘depressed’’ also under
stronger TCR and CD28 co-stimulation conditions. Due to lim-
iting cell numbers obtained from these rare patients, we were only
able to perform direct killing assays with CTLs from patients
CD46-1 and -2 (Supplementary Fig. 3d). However, given that the
level of degranulation (as measured by CD107a expression) cor-
related significantly with cytotoxic activity in CTLs (Supple-
mentary Fig. 3e), we suggest that it is appropriate to extrapolate
that optimal killing potency was also severely reduced in the
CTLs isolated from patients’ CD46-3 and -4 due to absent
autocrine CD46 activation.
Silencing of CD46 expression in CD8+ T cells isolated from
healthy donors using siRNA (Supplementary Fig. 3f, general
CD46 knockdown efficiency was 40 ± 8%) further supported the
data obtained using cells from CD46-deficient patients as it also
led to sub-optimal IFN-γ secretion, degranulation and granzyme
B expression (Fig. 3g–h) without affecting cell viability (Supple-
mentary Fig. 3g).
Altogether, these data demonstrate distinct functions for CD46
in CD4+ and CD8+ T cells: CD46 is obligatory for Th1 effector
induction but not for basal CTL activity, where it functions
instead to optimize effector responses.
Fig. 1 CD46 co-stimulation provides superior support for CTL activity. a CD46 expression on the surface of resting human CD4+ and CD8+ T cells
assessed by FACS analysis (n= 4, gating strategy in Supplementary Fig. 7a). b Comparison of IFN-γ, TNF-α and IL-10 secretion by CD3+ CD46-activated
T cells. Purified CD4+ and CD8+ T cells from healthy donors were left non-activated (NA) or stimulated with immobilized antibodies to CD3, CD3+CD28
or CD3+ CD46 and cytokines measured 60 h post activation (n= 5). c, d Degranulation (CD107a staining, (c)) and granzyme B expression (d) by CD8+
T cells upon CD46 co-stimulation. CD8+ T cells were stimulated as in (a) and CD107a and granzyme B expression assessed with left panels showing
representative cytometry images and right panels corresponding quantifications (n= 3, gating strategy in Supplementary Fig. 7b). e Killing activity of
CD46-activated CD8+ T cells. T cells were stimulated as depicted for 24 h and cytotoxic activity of differently activated CD8+ T cells towards DU145
target cells assessed 24 h post co-culture of T cells and DU145 cells (n= 4, gating strategy in Supplementary Fig. 7c). f Effect of CD46 co-stimulation on
CD8+ T-cell proliferation. Purified T cells were activated as indicated for 5 days and cell proliferation measured each day (n= 4) (black circles, non-
activated cells; green, blue, and red circles, CD3, CD3+ CD28 or CD3+ CD46-activated cells, respectively). g Effects of CD46 co-stimulation on naive and
memory CTLs. Purified human naive or memory CD8+ T cells (sorting gates in Supplementary Fig. 7d) were activated under depicted conditions for 60 h
and IFN-γ secretion, CD107a and granzyme B surface expression, and cytotoxic activity measured (n= 3). Error bars denote mean ± SEM (standard error of
the mean). *p < 0.05; **p < 0.01; ***p < 0.005; ns, statistically not significant. Statistical analyses were performed using One-way ANOVA with Tukey
Multiple Comparison test
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NLRP3 function is distinct in CD4+ and CD8+ T cells. We next
assessed the mechanisms by which CD46 may augment CTL
function. In CD4+ T cells, intrinsic NLRP3 inflammasome
assembly driven by intracellular C5 activation works synergisti-
cally with CD46 and is required for maintaining optimal levels of
IFN-γ secretion in Th1 cells11– we hence analyzed CD8+ T cells
for the presence of this crosstalk. Indeed, CD8+ T cells expressed
both C5a receptors, C5aR1 and C5aR2, at similar levels and
locations (C5aR1 exclusively intracellularly and C5aR2 intra- and
extracellularly) when compared to CD4+ T cells and also con-
tained intracellular stores of C5, from which they generated C5a
once stimulated (Fig. 4a–c). Similarly, CD8+ T cells expressed
NLRP3, whose expression was increased upon TCR activation
particularly in conjunction with CD46 co-stimulation (Fig. 4d).
However, and in contrast to CD4+ T cells, neither IL1B gene
transcription (Fig. 4e) nor active IL-1β secretion (Fig. 4f) were
significantly augmented in CD8+ T cells upon CD46 co-
stimulation. In line with these findings, addition of the canoni-
cal NLRP3 inflammasome inhibitor MCC95015 reduced IL-1β
and IFN-γ production in CD4+ T cells (Fig. 4g)11 but had no
effect on these cytokines in CD8+ T cells (Fig. 4g and Supple-
mentary Fig. 4a). Moreover, although CD8+ T cells contained
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Fig. 2 Autocrine CD46 engagement supports CTL activation. a Comparison of effects of TCR stimulation as well as CD28 and CD46 co-stimulation on IFN-
γ secretion by CTLs. Purified CD8+ T cells were activated with the depicted antibody combinations (for CD28 and CD46 either 1 μg/mL or 2 μg/mL at all
tested CD3 stimulation conditions) for 60 h and IFN-γ secretion measured (n= 3). b, c Extracellular and intracellular C3aR, C3, and C3a presence in resting
human CD8+ T cells. Freshly purified CD8+ T cells were either left non-permeabilized or were permeabilized and stained with antibodies to the C3aR, to
C3 and C3a and evaluated by FACS (b) or confocal microscopy (c, scale bar= 7 μm) for presence and localization of the respective antigens (data shown
are one representative of n= 3). d, e Effects of increasing TCR and CD28 activation on C3b generation, CD107a and granzyme B expression and cytokine
secretion. CD8+ T cells were left non-activated (NA) or activated with the depicted antibody combinations and C3b surface presence, CD107a and
granzyme B positivity (d, shows a representative FACS analysis of two similarly performed experiments; gray histograms, isotype controls; black
histograms, non-activated cells; blue histograms, no CD28 stimulation; green and red histograms, addition of 1 or 2 μg/mL α-CD28, respectively) and IFN-γ
production (e) measured at 12 h post activation (n= 3). The gating strategy for CD8+ T cells flow cytometry staining is shown in Supplementary Fig. 7b.
Error bars denote mean ± SEM. *p < 0.05; **p < 0.01; ns, statistically not significant; ctrl. Control. Statistical analyses were performed using One-way
ANOVA with Tukey Multiple Comparison test
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active caspase-1 (which is a key downstream product of NLRP3
inflammasome activation) with increased amounts observed
under all activation conditions (Supplementary Fig. 4b), MCC950
reduced active caspase-1 generation only in CD4+ T cells11, but
not in CD8+ T cells (Fig. 4h). Granzyme B production also
remained unaffected by MCC950 treatment (Fig. 4i) and we were
unable to detect IL-18, another cytokine activated by the NLRP3
inflammasome, in CD8+ T cells (Fig. 4j). We noticed, however,
that the NLRP3 protein translocated to the nucleus in substantial
amounts upon CD3+ CD46 activation (Supplementary Fig. 4c).
A divergent role for the NLRP3 inflammasome in CD4+ and
CD8+ T cells is further supported by our finding that CD8+
T cells from patients with CAPS, a series of autoinflammatory
diseases with gain of function NLRP3 gene mutations23
(Supplementary Table 3), functioned normally. We had pre-
viously demonstrated that uncontrolled NLRP3 inflammasome
activity in CD4+ T cells from these patients translated into
increased caspase-1 activity, IL-1β secretion and hyperactive Th1
responses, which could all be normalized with MCC950
treatment (Fig. 5a–b)11. In stark contrast, CD8+ T cells from
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these patients demonstrate no significant increase in IL-1β or
IFN-γ secretion, degranulation, granzyme B expression or
cytotoxicity (Fig. 5a–d and Supplementary Table 4). Furthermore,
proportions of naive vs. memory CD8+ T cells in the patients are
within the normal range (Supplementary Fig. 5a, b).
These data suggest that, although human CTLs harbor an
intracellular C5 system and express NLRP3, the intracellular C5
activation-driven formation of a canonical NLRP3 inflammasome
—as opposed to CD4+ T cells—is not one of the mechanisms by
which CD46 signals support optimal CD8+ T-cell effector
function.
CD46 augments cell metabolism for optimal CTL activity. To
pinpoint pathways driven by CD46 co-stimulation in CTLs, we
compared the gene expression profile of CD3+ CD46-activated
purified CD8+ T cells from three CD46-deficient patients (CD46-
2 to -4) and four sex- and age-matched healthy donors at 6 h post
activation via RNA-Sequencing technique. Approximately 2300
transcripts were differentially expressed (by at least two-fold at q-
value of 0.05 or less) upon CD3+ CD46 activation in CTLs from
healthy donors compared to 147 transcripts in patients with
CD46 deficiency (Fig. 6a and Supplementary Data 1). Nearly all
of the genes altered in patient cells were also differentially
expressed in healthy donors. In contrast, approximately 1900
differentially expressed transcripts were unique to healthy donors
(Fig. 6b). As in CD4+ T cells9, CD46 induced most strongly genes
connected with multiple metabolic pathways in healthy donor
CTLs (Supplementary Data 2). These included FASN (fatty-acid
synthase), FABP5 (fatty-acid binding protein 5), and SLC7A5
(coding for the L-type large neutral amino acid transporter
LAT1), which are key components of lipid/lipoprotein metabo-
lism and membrane solute transport, respectively (marked in
‘‘red’’ in Fig. 6c). Comparative gene arrays using CD8+ T lym-
phocytes from three healthy volunteers activated in vitro with
antibodies to CD3 alone versus CD3 and CD46 in combination
confirmed that the identified induced pathways are mostly driven
by CD46 co-stimulation and not TCR engagement alone (Sup-
plementary Fig. 6a, b and Supplementary Data 3).
Aligning with this, CD46 significantly increased LAT1 protein
expression (Fig. 6d, left panel) and activation of the amino acid
sensor mammalian target of rapamycin (mTOR), measured by
augmented phosphorylation of the downstream mTOR target S6
Kinase (S6K) (Fig. 6d, middle panel)24. mTOR-mediated
activation of fatty-acid reprogramming (which involves FABP5
and FASN) is critical for CD8+ T-cell proliferation, effector
function25 and survival of tissue-resident CD8+ T cells26,27.
Indeed, we observed that CD46 co-stimulation also increased
FASN protein expression significantly when compared to CD3
and CD3+ CD28-stimulated CD8+ T cells (Fig. 6d, right panel)
while reduction of CD46 expression significantly reduced FASN
gene transcription during activation (Supplementary Fig. 6c).
Furthermore, restraint of FASN activity through the specific
inhibitor C75 during CD3+CD28 and CD3+ CD46 activation
reduced IFN-γ secretion and degranulation by in vitro stimulated
T cells in a dose-dependent manner to about the levels observed
with CD3 activation alone (Fig. 6e) without affecting cell viability
(Supplementary Fig. 6d).
Importantly, equivalent induction changes in FASN, FABP5, or
SLC7A5 transcription in CD46-deficient CTLs were not evident
in the RNA-Sequencing analysis (Fig. 6f) and subsequent
quantitative PCR analyses showed indeed a significant diminu-
tion of FASN and FABP5 induction—and a trend for reduced
SLC7A5 expression—in CD3+CD46-stimulated CTLs from
CD46-deficient patients when compared to healthy donors
(Fig. 6g).
Altogether these data indicate that the mechanism by which
autocrine CD46 co-stimulation enhances CTL effector function
during CD8+ T-cell activation is—at minimum—through
augmentations in nutrient influx, mTOR activity, and fatty-acid
metabolism (Fig. 7).
Discussion
Here, we explored the role of CD46 signaling in human CD8+
T cells. A number of studies in recent years have prompted
substantial changes in our perception of the roles of complement.
It is now well recognized that local complement production
clearly orchestrates basic physiological processes of CD4+ T cells,
including cellular metabolism, survival, proliferation, and
autophagy28,29. Importantly, CD46 is ubiquitously expressed by
human, but not murine, immune cells30 and regulates activation
and secretion of intracellular C3 and C57. This self-contained
CD46-regulated autocrine-functioning C3–and–C5–system (the
complosome) is directly responsible for induction and contrac-
tion of human Th1 responses via direct regulation of nutrient
influx, glycolysis, mitochondrial activity, and inflammasome
assembly31–33. Patients with genetic CD46 (or C3) deficiency
suffer from recurrent bacterial and viral infections7, thus we
reasoned that the complosome may also be critical for the
function of human CD8+ T cells, a previously unexplored notion.
Our findings indicate the presence of a full-blown functional
complosome in CD8+ T cells, including surface CD46, intracel-
lular stores of C3 and C5 and generation of intracellular C3a and
C5a fragments upon T-cell activation, comparable to human CD4
+ T cells11. Moreover, we identified CD46 as a novel, key co-
stimulatory molecule driving optimal induction of both human
naive and memory CTL effector responses, including IFN-γ
Fig. 3 CD46 activation has distinct outcomes in CD4+ and CD8+ T cells. a CD46 expression on resting CD4+ and CD8+ T cells from patient CD46-1 (red
histograms) and a matched healthy donor (HD) (black histograms; gating strategy as in Supplementary Fig. 7a). b IFN-γ secretion by CD4+ and CD8+
T cells from patient CD46-1. Purified T cells were left non-activated (NA) or activated with the depicted immobilized antibodies and IFN-γ secretion
assessed (60 h). Data shown are mean values of each condition performed in duplicate. c Degranulation (CD107a) and granzyme B expression of CTLs
from patient CD46-1. Purified CTLs were activated with the indicated antibody combinations and CD107a and granzyme B expression measured at 60 h
(gray histograms, isotype controls; black histograms, non-activated cells; green, blue, or red histograms, CD3, CD3+ CD28, or CD3+ CD46 activation,
respectively; gating strategy shown in Supplementary Fig. 7b). d Cytotoxic activity of CTLs from patient CD46-1. CTLs from patient CD46-1 were CD3+
CD46-activated for 24 h and killing activity measured in comparison to CTLs from five HDs (gating in Supplementary Fig. 7c). e, f IFN-γ production and
degranulation capacity of CTLs from CD46-deficient patients CD46-1 to CD46-4. Purified CD8+ T cells from patients CD46-1 to -4 and from four sex- and
age-matched HDs were activated as in (b) and IFN-γ secretion (e) and CD107a and granzyme B+ cells (f, gating as in Supplementary Fig. 7b) measured (n
= 4). g, h Effect of CD46 protein knockdown on HD CTL effector function. CD8+ T cells from three different healthy donors were transfected with either
siRNA targeting CD46 mRNA or control siRNA for 48 h, then activated with immobilized antibodies to CD3 and CD46 for further 48 h and IFN-γ secretion
(g) and CD107a and granzyme B expression measured (h, gating as in Supplementary Fig. 7b; representative cytometry plots of three similarly performed
experiments; black histograms, control siRNA; purple histograms, CD46 siRNA) (n= 3). Error bars denote mean ± SEM. *p < 0.05; ***p < 0.005; ctrl.:
control. Statistical analysis was performed using One-way ANOVA with Tukey Multiple Comparison test
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production and cytotoxic activity. Importantly, autocrine CD46
engagement on CTLs, similar to that on CD4+ T cells, is driven
by TCR and CD28-supported intrinsic C3b generation, and is a
requirement for optimal CTL responses. A C3b-interacting
complement receptor/regulator that functions as murine homo-
log to human CD46 with regards to Th1 regulation and CTL
activation has not been identified, and current studies indicate
that CD28 is sufficient to drive glycolysis and OXPHOS needed
for the induction of CD4+ T-cell effector function in mice31. This
further substantiates the growing understanding that the mole-
cular mechanisms supporting successful T-cell activation down-
stream of key co-stimulators is distinct between mice and men.
Dysregulated CD46 engagement in CD4+ T cells contributes to
several Th1-mediated autoimmune states7,34 and a recent study
indicates that a novel mutation in the CD46 gene is also asso-
ciated with aberrant CTL responses in multiple sclerosis35, sug-
gesting strongly that our findings here have indeed implication
for CTL-driven diseases in humans. In mice, modulating intrinsic
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C3 activity (the equivalent of C3b-mediated CD46 engagement in
humans) in tumor-infiltrating lymphocytes can promote tumor
progression36. Altogether, these studies and our current work
suggest that understanding human-specific complement path-
ways in CTL biology could open avenues to novel therapeutic
approaches in cancer, vaccine development and/or
autoimmunity.
Mechanistically, CD46 signaling augmented TCR-induced
influx of amino acids, mTOR activation and lipid biosynthesis,
requisite events for normal CTL function27. CD46 deficiency,
either genetic or experimentally induced by protein knockdown
in healthy donor T cells, caused sub-optimal lytic activity and
IFN-γ production in CTLs, which would explain the predisposi-
tion of CD46-deficient patients to recurrent viral infections7 as
viral control requires both optimal CD4+ and CD8+ T-cell
activity.
Of note, an earlier study observed CD46-driven increase in
CD25, CD28, and tumor necrosis factor receptor superfamily,
member 4 (TNFRSF4 or OX40, CD134) expression in CD8+
T cells from healthy donors but no augmentation of IFN-γ
responses (effects on CTL cytotoxic activity were not assessed)17.
However, this study did not deplete CD56+ cells (natural killer
(NK) and NK T cells) from their cultures, which impact heavily
on CD8+ T-cell function, and could explain the discrepancy in
observed outcomes of CD46 co-stimulation of CTLs between the
two studies. This is supported by recent work published by
Hansen and colleagues that confirms our finding as this group
also observed increased IFN-γ secretion by human CTLs acti-
vated in the presence of anti-CD46 antibodies37. Cytotoxic
activity, or CD46-driven downstream signals, however, were not
explored in this work.
Interestingly, although CD46 was a key co-stimulator in both
populations, we found that the role of CD46 differs in CTLs
compared to helper T cells. In particular, CD46-mediated signals
are obligatory for induction of Th1 differentiation in CD4+
T cells7,9,13 but not obligatory for initiation of effector function in
CD8+ T cells per se. Instead, the complosome was critical for
optimal CTL activity. This may reflect inherent differences
between T helper cells, which undergo fate decisions that differ-
entiate them to specific effector lineages, and CTLs, which have
more limited functional repertoires and require no additional
differentiation.
Furthermore, engagement of CD46 on expanding Th1 cells
induces high IL-10 co-production and is required to transition
these cells into a suppressive and contracting phenotype4.
Without this switch into IL-10 co-production, activated and
expanding CD4+ T cells fail to contract Th1 responses and
remain hyperactive, as seen in rheumatoid arthritis4, multiple
sclerosis14, and systemic lupus erythematosus34. We observed
that CD8+ T cells failed to induce significant levels of IL-10 upon
CD46 stimulation, possibly reflecting the short half-life of CTL
responses and a dispensable role of autocrine IL-10 for contrac-
tion of these responses.
Although our current study indicates that CD46-driven sig-
naling events are distinct between CD4+ and CD8+ T cells, a
common theme is their impact on cell metabolic pathways reg-
ulating T-cell effector function. We have previously demonstrated
that CD46 is critically required to regulate glucose and AA influx
and to drive glycolysis and OXPHOS in CD4+ T cells9. We
demonstrate here that in CTLs, ligation of this surface protein
also mediates AA influx and augments cellular fatty-acid meta-
bolism, supporting the assertion that the complosome serves
critical novel and non-canonical roles in cell biology. This notion
aligns well with the growing understanding that other classical
danger sensing or pattern recognition receptor (PPR) systems
such as the toll-like receptors (TLRs), the nod-like receptors
(NLRs) and different inflammasomes engage in the functional
crosstalk with a series of metabolic checkpoint systems via
inducing and/or recognizing metabolic changes to control both
cell activation and homeostasis38. A crosstalk between the com-
plosome and the canonical NLRP3 inflammasome that modulates
oxygen metabolism is also an integral part of normal human Th1
biology: CD46 stimulation increases intracellular C5a production
and intracellular C5aR1-dependent mitochondrial ROS genera-
tion, which leads to the assembly of the NLRP3 inflammasome in
CD4+ T cells11. NLRP3 inflammasome-induced caspase-1 acti-
vation and secretion of mature IL-1β then support sustained Th1
activity in an autocrine fashion. NLRP3 inhibition or reduction of
intracellular C5aR1 expression strongly impairs human Th1
responses. Conversely, CD4+ T cells from CAPS patients, which
express constitutively-active NLRP3, produce uncontrolled IL-1β
and have pathologically increased Th1 activity that can be nor-
malized by the specific NLRP3 inhibitor MCC95011,15. Because
CD8+ T cells express the required complement components and
receptors as well as NLRP3, our finding that an intrinsic com-
plosome—inflammasome—axis is not required for normal IFN-γ
production (or cytotoxicity) in CTLs was unexpected: although
we detected active caspase-1 and low amounts of mature IL-1β in
stimulated CD8+ T cells, neither activation of caspase-1 nor
production of IL-1β could be inhibited by MCC950. Furthermore,
MCC950 had no effect on IFN-γ secretion or killing ability of
CTLs, which aligns fully with our finding that CD8+ T cells from
CAPS patients, in contrast to their CD4+ T cells, have no
intrinsically altered phenotype. While the significance of active
caspase-1 and/or low-level IL-1β secretion in human CTLs
remains to be defined, TNF-α can drive NLRP3 inflammasome-
Fig. 4 Divergent roles for NLRP3 in CD4+ and CD8+ T cells. a, b Extracellular and intracellular C5aR1, C5aR2, C5 and C5a in resting human CD8+ T cells.
Freshly purified CD8+ T cells were evaluated for extra- and intracellular C5aR1 (green histograms), C5aR2 (red histograms), C5 and C5a expression by
FACS (a) or confocal microscopy (b, scale bar= 7 μm). c Levels of C5aR1, C5aR2, and C5 expression in resting CD4+ and CD8+ T cells and C5a
generation in activated CD8+ T cells (n= 3). d Effect of CD46 co-stimulation on NLRP3 expression in T cells. T cells from healthy donors were left non-
activated (NA) or stimulated with the depicted antibodies and NLRP3 expression measured 60 h post activation (n= 4). Upper panels show a
representative cytometry plot of NLRP3 expression and lower panels the corresponding quantifications (gray histograms, isotype controls; black
histograms, non-activated cells; green, blue, or red histograms, CD3, CD3+ CD28, or CD3+ CD46 activation, respectively; gating strategy for Fig. 4a–d is
shown in Supplementary Fig. 7b). e, f Effect of CD46 co-stimulation on IL1B gene transcription at 6 h post activation ((e) n= 2)) and IL-1β secretion ((f) n
= 4)) in CD4+ and CD8+ T cells at 60 h post activation (for an uncropped image of panel (e), see Supplementary Fig. 8). g Impact of MCC950 on IL-1β
and IFN-γ production from CD46-activated T cells. T cells were CD3+CD46-activated with or without MCC950 (10 μM) and cytokine production
determined (60 h) (n= 4). h, i Effects of MCC950 on active caspase-1 generation and granzyme B expression in CTLs. CTLs were treated as in (g) and
active caspase-1 ((h) n= 6 and granzyme B measured (i, n= 3). j TCR and CD46 activation fail to induce IL-18 in human CTLs (72 h post activation, n= 4).
Error bars denote mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.005; ns, not significant; ctrl, control. Statistical analyses were performed using One-way
ANOVA with Tukey Multiple Comparison test or the Paired Student’s t-test where appropriate
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independent caspase-1 maturation39 and this pathway may be
operative here. The function of NLRP3 in CD8+ T cells also
remains currently unresolved. We noted that substantial amounts
of NLRP3 translocate to the nucleus in human CD8+ T cells
upon CD3+ CD46 activation (Supplementary Fig. 4c) and future
work may possibly uncover a non-canonical nuclear function for
NLRP3 in human CTLs as it was previously observed in mouse
CD4+ T cells16. Similarly, the definition of the exact role(s) of the
autocrine C5 system in human cytotoxic T cells requires further
work as well. Antiviral CTL activity is reduced in C3 or C5ar1-
deficient mice and augmented in Daf–/– mice (because of
unrestrained local C3a and/or C5a generation as the decay
acceleration factor (DAF, CD55) is a complement activation
inhibitor) supporting that C3 and C5 activation fragments are
indeed involved in regulating CD8+ T-cell responses40–42. We
had previously shown that the intracellular C5 system in human
CD4+ T cells induces mitochondrial ROS production, which is
also required for cell proliferation11,43, hence, assessing for a
potential role of C5-regulated mitochondrial activity in CTLs may
be a suitable starting point. Nevertheless, our observation here
that crosstalk between the complosome and the NLRP3 inflam-
masome is not required for normal CTL activity in humans
suggests that the NLRP3-targeted therapeutics currently under
assessment will not interfere directly with protective CTL
responses.
In sum, our findings establish CD46 as a key modulator of both
CD4+ and CD8+ T-cell immunity through the mediation of
nutrient influx and regulation of key metabolic pathways but they
also further emphasize an emerging concept in the literature,
namely that innate immune sensor systems have critical but
divergent roles among different immune cell subpopulations and
between mice and men.
Methods
Healthy donors and patients. Blood samples from healthy donors and patients
were obtained and processed with ethical and institutional approvals. Three
patients with deficiency in CD4613,21,22 (patients CD46-1 to -3) were recruited to
King’s College London (REC number 09/H0803/154; KCL Ethics Committee and
Wandsworth Research Ethics Committee) and one patient (CD46-4) was recruited
to the Nottingham University Hospital/National Complement Therapeutics Center
(REC number 01/2/038; North East-York Research Ethics Committee) with key
information on the patients summarized in Supplementary Table 1. Four adult
patients with cryopyrin-associated periodic syndrome (CAPS) were recruited at the
National Amyloidosis Center, University College London (UCL Ethical Approval
Committee, REC reference number 06/Q0501/42) with key information on the
patients summarized in Supplementary Table 3. In all experiments that involved
T cells from the CD46-deficient patient or from CAPS patients, T cells from age-
and sex-matched healthy volunteers were used as controls. Informed consent was
obtained from all human participants of this study.
Antibodies, agonists/antagonists and inhibitors. Cell-stimulating monoclonal
antibodies to human CD8+ T cells were bought from BD Biosciences, San Diego,
CA (anti-hCD28, CD28.2, cat. 555726), purified from a specific hybridoma (anti-
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hCD3; OKT-3) or generated in-house (anti-CD46; TRA-2-10)44 and used at the
indicated concentrations under the T-cell stimulation protocol. Antibodies against
human CD4 eFluor 450 (OKT4, cat. 48-0048-42, 0.25 μg/mL), CD46 PE (clone
8E2, cat. 12-0469-42, 2.0 μg/mL), CD56 APC (MEM-188, cat. MA1-19462, 1.0 μg/
mL) and CD107a FITC (eBioH4A3, cat. 11-1079-42, 3.0 μg/mL) were bought from
eBioscience (San Diego, CA). Anti-human granzyme B FITC (GB11, cat. 560211,
5.0 μL/test), C3aR PE (hC3aRZ8, cat. 561178, 3.0 μL/test), CD45RA PECy7 (5H9,
cat. 561216, 2.0 μL/test), and CD45RO BV711 (UCHL1, cat. 563722, 2.0 μL/test)
antibodies were purchased from BD Biosciences (San Jose, CA, USA). Anti-human
NLRP3 (ab4207, 5.0 μg/mL), C5 (ab11898, 1.0 μg/mL) and C5a neo-epitope
(ab11878) were produced by Abcam (Cambridge, UK). Antibodies to human
C5aR1 FITC (S5/1, Santa Cruz Biotechnology, CA, cat. sc-53795, 5.0 μg/mL), C3
(GW20073F, Sigma-Aldrich, 5.0 μg/mL), CD8a (RPA-T8, PerCPCy5.5 cat. 301032
and PECy7 cat. 301012, 2.0 μL/test) and C5aR2 PE (1D9-M12, cat. 342404, 2.0 μL/
test) (both from Biolegend, Cambridge, UK), phosphorylated p70S6 Kinase (9205
S; 0.5 μg/mL) and LAT1 (5347; 1 μg/mL) (both from Cell Signaling Technology,
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Fig. 6 CD46 co-stimulation augments nutrient influx and fatty-acid synthesis. a, b Differentially expressed genes in CD8+ T cells of four healthy donors
(HD) and three CD46-deficient (CD46-def.) patients (CD46-2 to -4) upon CD3+CD46 activation at 6 h (a) and Venn diagram indicating overlap
between differentially expressed transcripts (b). c Heatmaps comparing non-activated (NA) and CD3+ CD46-activated (6 h) HD CTLs with focus on
genes involved in lipid/lipoprotein metabolism (left), transmembrane solute transport pathways (right), and FABP5 (left below). d Effect of CD46 co-
stimulation on LAT1 and FASN expression and on mTOR activation. CD8+ T cells (gated as in Supplementary Fig. 7b; gray histograms, isotype controls;
black histograms, non-activated cells; blue, green, or red histograms, CD3, CD3+ CD28, or CD3+ CD46 activation, respectively) from HDs were left NA
or stimulated as depicted and LAT1 and FASN expression and mTOR activity (70S6K phosphorylation) measured 48 h post activation (n= 4). e Effect of
FASN inhibition on IFN-γ production and degranulation of CTLs. CD8+ T cells were activated as in (d) in the presence or absence of the FASN inhibitor C75
and IFN-γ secretion and CD107a expression measured at 48 h post activation (n= 3–4; gray bars, carrier addition; white bars, addition of 5 μM C75; black
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CD46-2, and CD46-4 (light red bars), and three matched HDs (light blue bars) at 6 h post activation (n= 3). Error bars denote mean ± SEM. *p < 0.05; **p
< 0.01. Statistical analyses were performed using One-way ANOVA with Tukey Multiple Comparison test or the Paired Student’s t-test where appropriate
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Danvers, MA) were purchased while the anti-human C3a neo-epitope antibody
was a gift from Jörg Köhl (1:100 dilution; University of Lübeck, Germany)45. The
anti-human C5a antibody was also biotinylated in house using the APEX™ Biotin-
XX Antibody Labeling Kit (Life Technologies Ltd, Paisley, UK) an used at a final
concentration of 0.2 μg/mL. The anti-human fatty-acid synthase (FASN) antibody
(EPR7466, 0.5 μg/mL) was obtained from Abcam. The secondary antibodies used
included: anti-rabbit IgG H+ L chain Alexa Fluor 594 (ab150076), anti-goat IgG
H+ L chain PE (ab7004) and anti-goat IgG H+ L chain Alexa Fluor 488
(ab150129), all from Abcam. An anti-mouse IgG Alexa Fluor 488 (A11001), and
anti-chicken IgG H+ L chain Alexa Fluor 488 (A11039), both from Molecular
Probes (Paisley, UK) and used for the confocal microscopy experiments. The
secondary antibodies were all used at 1:200 final dilution. APC-conjugated strep-
tavidin was bought from Biolegend (cat. 405207) and used at a final dilution of 1.0
μg/mL.
Recombinant human IL-2 was provided by Dr. Christine Pham (Washington
University in Saint Louis, MO) and the specific C5aR2 agonist (RHYPYWR) was
generated by T. Woodruff and P. Monk (Sheffield University, UK)46 and used at
100 μM. The NLRP3 inflammasome antagonist MCC95015 was provided by M.
Cooper (University of Queensland, Brisbane, AUS) and L. O’Neill (Trinity College,
Dublin, IRL) and used at 10 μM, whereas the fatty-acid synthase (FASN) inhibitor
C75 was bought from Sigma-Aldrich (C5490; Saint Louis, MO, USA) and used at 5
or 10 μM. The cathepsin L inhibitor was also purchased from Sigma-Aldrich
(SCP0010) and used at 50 nM.
Cell isolation and stimulation. Peripheral blood mononuclear cells (PBMCs) from
healthy volunteers and patients were isolated via centrifugation with Ficoll-Paque
PLUS (GE Healthcare, Rockville, MD, USA). CD4+ and CD8+ T cells were sub-
sequently isolated either via cell-sorting or via magnetic bead separation. For cell-
sorting, PBMCs were treated for 10 min with human FcR blocking reagent (Mil-
tenyi Biotec Ltd, Bisley, UK) and then stained with anti-human CD4, CD8a, and
CD56. Cell-sorting was subsequently performed using a BD FACSAriaTM II Cell
Sorter (Flow Core facility, King’s College London). CD4+ and CD8+ T lympho-
cytes were sorted, respectively, as CD4+CD56− and CD8+CD56− cells with cell
purity consistently ≥ 99%. For isolation via magnetic beads, contaminating CD56+
natural killer and natural killer T cells were first depleted by positive selection using
the CD56+ Cell Isolation Kit (Miltenyi Biotec, Auburn, CA, USA), and CD8+ or
CD4+ T cells were then purified using the CD8+ or CD4+ Cell Isolation Kit-II
(both from Miltenyi Biotec, Auburn, CA, USA), following the manufacturer’s
instructions. The purity of final cell populations was consistently ≥ 95%.
For human T-cell stimulation, 48-well plates were coated overnight at 4 °C with
2 μg/mL of anti-CD3 (for CD4+ T cells and 0.25 μg/mL for CD8+ T cells), anti-
CD28 (2 μg/mL, BD Biosciences, Oxford, UK), and anti-CD46 (2 μg/mL GB24,
generated in house) antibodies diluted in modified dPBS (Hyclone, Logan, UT,
USA). T cells were resuspended in RPMI 1640 (Gibco Gaithersburg, MD, USA)
supplemented with 1% penicillin-streptomycin, 200 mM L-glutamine (both from
Sigma-Aldrich, Saint Louis, MO, USA), 10% fetal calf serum (Gibco, Gaithersburg,
MD, USA), and 25 U/mL recombinant human IL-2 at 5 × 105 cells/well and
stimulated for in an incubator at 37 oC and 5% CO2 for time points indicated in the
respective experiments. Note, were the usage of specific inhibitors or agonists were
indicated in the experiments, cells were preincubated for 15 min with respective
reagents or carrier control and then further cultured and activated.
Cytokine measurements and detection of active caspase-1. Cytokine secretion
from activated human T cells into cell supernatants was quantified using the
human Th1/Th2/Th17 Cytometric Bead Array (BD Biosciences, San Jose, CA,
USA) following the manufacturer’s instructions. Samples were acquired on a
Fortessa LSRIII supported by FACS diva software (BD Biosciences, San Jose, CA,
USA). Data were analyzed by FCAP array software (Soft Flow Hungary Ltd, Pecs,
Hungary). IL-1β was measured using the Human IL1B Duo Set ELISA kit (R&D
system Minneapolis, MN, USA) following the manufacturer’s instructions in
combination with the SIGMAFASTTM OPD tablets (Sigma-Aldrich, Saint Louis,
MO, USA) for substrate detection. Generation of cleaved and active caspase-1 in
human cells was monitored using the Green FLICA Caspase-1 Assay Kit
(ImmunoChemistry Technologies, Bloomington, MN, USA) according to the
manufacturer’s protocol with subsequent FACS analysis.
Cell proliferation assay. For the measurement of CD8+ T-cell proliferation, the
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) from Promega
(Madison, WI, USA) was used. This is a colorimetric method for determining the
number of viable cells in proliferation, cytotoxicity, or chemosensitivity assays.
Freshly purified CD8+ T cells were either left non-activated or activated with
immobilized activating antibodies to CD3 alone or to CD3+ CD28 or CD3+
CD46 in combination in 150 μL in 96-well plates. Cell proliferation was measured
at days 1–5 by adding 20 microliter of the CellTiter 96® AQueous One Solution
Reagent directly to culture wells, incubating for 1–4 h and then recording absor-
bance at 490 nm with a 96-well plate reader. The quantity of formazan product as
measured by the amount of 490 nm absorbance is directly proportional to the
number of living cells in culture.
Cytotoxicity assay. The prostate cancer cell line DU145 (a gift from Dr. Hide
Yamamoto, King’s College London, UK) was used as source of target antigen
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presenting cells to measure cytotoxic activity of human CD8+ T cells. DU145 cells
were cultured in RPMI 1640 media (Gibco, Gaithersburg, MD, USA), with 1%
penicillin-streptomycin and 2 mM L-glutamine (all from Sigma-Aldrich, Saint
Louis, MO, USA) in 24-well plates to 90% confluence. Bead-purified CD8+CD56–
T cells were labeled with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE)
(Molecular Probes, Eugene, OR, USA) in PBS and then either left non-activated or
activated with antibodies to CD3 alone, CD3+ CD28 or CD3+ CD46 for 24 h and
then plated onto the layer of DU145 cells at a 1 (DU145): 8 (T cell) ratio. After 12 h
of co-culture, DU145 and T cells were harvested via trypsinization and cell mix-
tures stained with Annexin V in Annexin V binding buffer, followed by addition of
0.5 μg/mL propidium iodide (PI) (all from BD Biosciences, San Jose, CA, USA).
Cells were analyzed using a FACS Calibur cytometer for Annexin V and PI-
staining, supported by CellQuest Pro software (both from BD Biosciences, San Jose,
CA, USA) with DU145 target cells identified as CFSE-negative cells. Annexin V
and PI double-positive cells were considered in the evaluation of % of killed DU145
cells. Annexin V single-positive cells, Annexin V/PI double-positive cells and PI
single-positive cells were identified as early apoptotic, late apoptotic, and necrotic
cells, respectively.
Flow cytometry. Cells were stained for desired surface markers in PBS with 0.5%
BSA and 2mM EDTA (both from Sigma-Aldrich, Saint Louis, MO, USA), the
addition of the appropriate antibody and isotype control antibody combinations as
well as the LIVE/DEAD Cell Viability Assay (Life Technologies, Carlsbad, CA,
USA) for 30 min on ice. For intracellular stainings, cells were first fixed and per-
meabilized utilizing the Cytofix/Cytoperm kit (BD Biosciences, San Jose, CA, USA)
and preincubated for 10 min with human FcR blocking reagent (Miltenyi Biotec,
Auburn, CA, USA) before addition of the desired antibodies and incubation for 30
min on ice. If the initial staining was performed with non-conjugated antibodies,
cells were washed twice with PBS and then incubated for an additional 30 min on
ice with a desired fluorochrome-conjugated secondary antibody or isotype control.
Cells were washed again and data acquired utilizing a Fortessa LSRIII supported by
FACS diva software (BD Biosciences, San Jose, CA, USA), and analyzed using the
FlowJo 10.0.8 software (Ashland, OR, USA).
Confocal microscopy. T cells were fixed, permeabilized, and stained as described
for intracellular stainings performed for flow analyses. Stained cells were mounted
onto glass slides using VECTASHIELD media with DAPI (Vector labs, Burlin-
game, CA, USA), covered with a cover glass and sealed using nail polish. Images
were subsequently acquired at room temperature with a Nikon A1R confocal
microscope (Nikon Imaging Centre, KCL) using a 100 x oil immersion objective,
and obtained pictures analyzed using the NIS Elements software version 4.03
(Nikon, Tokyo, JP).
RNA extraction, cDNA synthesis, and RT-PCR. RNA was extracted from T cells
using the RNeasy Mini kit with on-column DNAse digestion (both from QIAGEN,
Hilden, Germany), following the manufacturer’s instructions. RNA concentration
(A260) and purity (A260/A280 ≈ 2.0) was monitored using the spectrophotometer
NanoDrop 1000 (Thermo Fisher, Waltham, MA). Reverse transcription to cDNA
was performed utilizing the RevertAid H Minus First Strand cDNA Synthesis Kit
according to the manufacturer’s suggestions (Thermo Fisher Scientific, Waltham,
MA, USA).
Real-Time PCR for CD46 CYT-1 and CYT-2, IL1B and ACTB was performed
using 1 x Taqman Universal Mastermix (Applied Biosystems, Foster City, CA,
USA). CYT-1 primers: forward 5ʹ-TTGTCCCGTACAGATATCTTC–3ʹ; reverse 5ʹ-
CTTCTCAGAGAGAAGTAAATTTT-3ʹ; CYT-1 antisense probe: 5ʹ- AGTTAGGT
ATGTGCCTTTCTTCTTCCTCC-3ʹ; CYT-2 primers: forward 5ʹ- GGAGGAAGAA
GAAAGGGAAAGC-3ʹ; reverse 5ʹ- TCAGCCTCTCTGCTCTGC-3ʹ; CYT-2
antisense probe: 5ʹ- AGATGGTGGAGCTGAATATGCCACTT-3ʹ; IL1B primers:
forward 5ʹ-CTCGCCAGTGAAATGATGGCT-3ʹ; reverse: 5ʹ-GTCGGAGATTC
GTAGCTGGAT-3ʹ; ACTB primers: forward: 5ʹ-ACGGCCAGGTCATCACCATT
G-3ʹ; reverse: 5ʹ-AGTTTCGTGGATGCCACAGGAC-3ʹ. PCR amplification was
performed in an ABI Prism 7900HT thermocycler (Applied Biosystems) for 2 min
at 50 °C, 10 min at 95 °C, followed by 40 cycles of combined 15 s at 95 °C and 1 min
at 60 °C. The sequence detector SDS 2.4 software (Applied Biosystems) was used to
export the threshold cycles (Ct) values. Expression of the target gene was
normalized using the endogenous gene 18S ribosomal RNA (18S rRNA). The
relative quantification (RQ) of CYT-1 vs. CYT-2 presence was performed using the
ΔΔCt method47, where: ΔCT= Ct (CYT-1 or CYT-2) – Ct (18S rRNA), ΔΔCt=
ΔCt (CD8+ cells) – (ΔCt CD4+ cells), RQ= 2−ΔΔCt.
Probes and primers used to detect FASN, FABP5, SLC7A5, and RPL7 (for
transcript expression normalization) transcripts were purchased from Thermo
fisher. Their respective sequences are proprietary and are hence not publicly
available. The hyperlinks below provide the padded amplicon sequence and
denotes the general targeting area for each gene.
FASN
(Hs01005622_m1; http://www.ncbi.nlm.nih.gov/nuccore/NM_004104.4?report
= fasta&log$= seqview&format= text&from= 249&to= 549),
FABP5
(Hs02339439_g1;
http://www.ncbi.nlm.nih.gov/nuccore/NM_001444.2?report= fasta&log$=
seqview&format= text&from= 314&to= 614), and
SLC7A5
(Hs01001189_m1; http://www.ncbi.nlm.nih.gov/nuccore/NM_003486.5?report
=&fasta&og$= seqview&format= text&from= 1210&to= 1510)
RPL7 (Hs02596927_g1; http://www.ncbi.nlm.nih.gov/nuccore/NM_000971.3?
report= fasta&log$= seqview&format= text&from= 165&to= 465).
The uncropped blot for the IL1B RNA measurement shown in Fig. 4e is
displayed in Supplementary Fig. 8.
CD46 RNA silencing. siRNAs targeting CD46 mRNA and control scrambled
siRNA were purchased from Origene (Rockville, MD, USA) and delivered at a final
concentration of 15 nM (with a mixture of three different siRNA at 5 nM each or
scramble control at 15 nM) into primary human CD8+ T cells by transfection with
Lipofectamine RNAiMAX (Life Technologies, Paisley, UK) following the manu-
facturer’s instructions in the presence of 50 ng/mL of recombinant human
IL-15 and activating antibodies to CD3 (0.25 μg/mL) and CD28 (2 μg/mL) for 48 h.
Microarray data generation and analysis. Transcriptome profiling was per-
formed by the KCL Genomic Centre (London, UK) utilizing Illumina chip Human
HT-12 v4 Expression BeadChip (Illumina, San Diego, CA, USA) on RNA obtained
from CD8+ T cells freshly isolated via cell-sorting (CD8+, CD4–, CD56–) from the
blood of three different healthy donors. Purified T cells were activated with
immobilized antibodies to CD3 (0.25 μg/mL) either alone or in combination with
immobilized antibodies to CD46 (2 μg/mL) for 6 h in media supplemented with 25
U/mL of recombinant human IL-2. Expression data were analyzed with the Partek
Genomics Suite (Partek Inc., St. Louis, MO, USA) version 6.6 and Gene Set
Enrichment Analysis, GSEA (Broad Institute of MIT and Harvard, USA) with a
normalized enrichment score of 1.8 to derive normalized enrichment score (NES),
nominal p-value and FDR q-value. Supplementary Excel File 3 summarizes the list
of annotated genes and normalized read values from microarrays and volcano plot
for Supplementary Fig. 6a, b.
RNA-Seq data generation and analysis. The sequencing libraries were con-
structed from 10 pg–10 ng of total RNA using the Takara Bio USA’s SMART-Seq
V4 Ultra Low Input RNA Kit for Sequencing (Cat # 634888) following the
manufacturer instruction. Briefly, full-length cDNA synthesis was performed
using oligo-dT and SMART oligos and the Illumina sequencing adaptors and
barcodes incorporated into the final library by PCR. The fragment size of the
RNAseq libraries was verified using the Agilent 2100 Bioanalyzer (Agilent, Santa
Clara, CA, USA) and the concentrations determined using the Qubit instrument
(Life Technologies, Carlsbad, CA, USA). The libraries were loaded onto the
Illumina HiSeq 3000 machine (Illumina, San Diego, CA, USA) for 1 × 50 bp
single end read sequencing and generated about 55 M reads per sample. The.
fastq files were generated using the bcl2fastq software (Illumina) for further
analysis. Quality controls of raw sequencing reads were assessed using FastQC
tools48. If required, adapter sequences and low-quality bases were trimmed using
Cutadapt49. Reads were mapped against the reference human genome (GRCh38)
50 using STAR51 and read counts for each gene in GENECODE annotation v25
were generated using featureCounts52. Differential expression analysis was
performed using the DESeq2 R package53. Differentially expressed genes were
considered as those with fold change of at least 2 in either direction at q-value of
0.05 or less. Gene set enrichment tests for canonical pathways were performed
using GSEA (Broad institute)54.
Statistical analysis. Statistical analyses were performed using regression analysis,
the One-way analysis of variance (ANOVA) with Tukey Multiple Comparison test
or the Paired/Unpaired Student’s t-test and Bonferroni correction where appro-
priate (GraphPad Prism software, La Jolla, CA, USA). Data were assessed for
normal distribution using the D’Agostino-Pearson test. Data were expressed as
mean ± standard error of the mean (SEM), and statistical significance was attrib-
uted to p values < 0.05.
Data availability
The sequencing and microarray data have been deposited with the Gene Expression
Omnibus under the Accession number GSE119919.
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